Janux Therapeutics Inc is a clinical-stage biopharmaceutical company developing tumor-activated immunotherapies for cancer. The proprietary technology of the company has enabled the development of distinct bispecific platforms: Tumor Activated T Cell Engagers (TRACTr), Tumor Activated Immunomodulators (TRACIr), and Adaptive Immune Response Modulator (ARM) platforms. The TRACTr platform produces T cell engagers (TCEs) with a tumor antigen-binding domain and a CD3 T cell binding domain, while the TRACIr platform produces bispecifics with a tumor antigen-binding domain and a costimulatory CD28 binding domain.
Last trade$10.67
Day change-$0.25 (-2.29%)
Day range$10.53 – $11.19
Volume367,629
Market cap$668M
OpenXNAS
Fundamentals
Key company ratios and reported financial statements.
Source: Massive.com
Key ratios
Valuation
Market capitalization
$668.12M
Price / earnings
—
Price / book
0.73×
Price / sales
28.69×
EV / sales
26.89×
EV / EBITDA
-4.55×
Profitability
Earnings per share
-$1.63
Return on assets
-10.15%
Return on equity
-10.95%
Dividend yield
0%
Liquidity and leverage
Debt / equity
0×
Current ratio
17.69×
Quick ratio
17.69×
Cash ratio
0.77×
Cash flow
Price / cash flow
—
Price / free cash flow
—
Free cash flow
-$54.16M
Ratios use trailing-twelve-month financials and market data as of
Nov 16, 2026.
Financial statements
Income and cash flow amounts are for the period; balance sheets are point-in-time
snapshots. Amounts are shown in USD. Latest 8 quarterly or 5 annual periods are
displayed when available.
Income statement for JANX, quarterly periods
Line item
Q3 FY2026 Sep 30, 2026
Q2 FY2026 Jun 30, 2026
Q1 FY2026 Mar 31, 2026
Q4 FY2025 Dec 31, 2025
Q3 FY2025 Sep 30, 2025
Q2 FY2025 Jun 30, 2025
Q1 FY2025 Mar 31, 2025
Q4 FY2024 Dec 31, 2024
Revenue
$9.29M
$10.27M
$3.73M
$0
$10M
$0
$0
$0
Cost of revenue
$0
$0
$0
$0
$0
$0
$0
$0
Gross profit
$9.29M
$10.27M
$3.73M
$0
$10M
$0
$0
$0
Selling, general and administrative
$9.98M
$10.96M
$11.13M
$10.85M
$10.62M
$10.45M
$9.84M
$8.22M
Research and development
$30.57M
$30.99M
$26.81M
$31.55M
$34.63M
$34.66M
$25.06M
$20.81M
Total operating expenses
$40.55M
$41.96M
$37.95M
$42.4M
$45.25M
$45.12M
$34.9M
$29.02M
Operating income
-$31.26M
-$31.69M
-$34.21M
-$42.4M
-$35.25M
-$45.12M
-$34.9M
-$29.02M
Interest expense
$0
$0
$0
$0
$0
$0
$0
$0
Income before taxes
-$21.57M
-$21.97M
-$24.36M
-$31.95M
-$24.31M
-$33.86M
-$23.51M
-$20.22M
Income taxes
$0
$0
$0
$0
$0
$0
$0
$0
Net income
-$21.57M
-$21.97M
-$24.36M
-$31.95M
-$24.31M
-$33.86M
-$23.51M
-$20.22M
Net income attributable to common shareholders
-$21.57M
-$21.97M
-$24.36M
-$31.95M
-$24.31M
-$33.86M
-$23.51M
-$20.22M
EBITDA
-$30.8M
-$31.23M
-$33.74M
-$41.93M
-$34.75M
-$44.58M
-$34.38M
-$28.51M
Basic earnings per share
-$0.34
-$0.35
-$0.39
-$0.51
-$0.39
-$0.55
-$0.38
-$0.36
Diluted earnings per share
-$0.34
-$0.35
-$0.39
-$0.51
-$0.39
-$0.55
-$0.38
-$0.36
Recent news
Company coverage with links to the original publishers.
Ensign Group reported Q3 2026 earnings of $2.03 per share, beating consensus estimates of $1.94 by 4.64%, but revenues of $1.48 billion missed expectations by 0.71%. The company has beaten EPS estimates in all four recent quarters but topped revenue estimates only once. With a Zacks Rank #2 (Buy) rating and the Medical - Nursing Homes industry in the top 13% of performance, the stock is expected to outperform the market near-term, though it has underperformed the S&P 500 year-to-date.
Iovance Biotherapeutics shares surged 31.5% to $14.45 after the company raised its full-year 2026 revenue guidance to $410-$420 million from $350-$370 million. The stock is expected to report quarterly revenues of $106.85 million (up 58.4% year-over-year) with a loss of $0.12 per share. However, analysts note that without recent earnings estimate revisions, the stock's momentum may not sustain, and the company carries a Zacks Rank #3 (Hold) rating.
As prostate cancer incidence rises with advanced-stage diagnoses increasing, four pharmaceutical companies are advancing treatments. Pfizer and Novartis, with established prostate cancer franchises, await FDA decisions on label expansions for Talzenna/Xtandi and Pluvicto respectively. Candel and Janux, earlier-stage developers, are preparing regulatory filings and advancing clinical programs in this growing market.
Janux Therapeutics announced a collaboration and exclusive worldwide license agreement with Bristol Myers Squibb worth up to $800 million. Janux will receive $50 million in upfront and near-term milestone payments, with Bristol Myers Squibb handling subsequent development and commercialization of novel immunotherapies for solid tumors. The deal validates Janux's tumor-activated platform technology.
Janux Therapeutics stock rose nearly 12% after an analyst raised his price target, though he maintained a 'sector perform' rating. The company also launched a $300 million secondary stock offering to advance its cancer treatment pipeline.
Dividends
Declared distributions and recorded event dates. Forecasts are not
shown.
Updated daily
No declared upcoming dividend found.
No prior dividend records found.
Stock splits
Historical share-structure events and their execution dates.